Left atrial pathological degeneration assessed by integrated backscatter transesophageal echocardiography as a predictor of progression to persistent atrial fibrillation: Results from a prospective study of three-years follow-up by unknown
CARDIOVASCULAR 
ULTRASOUND
Kubota et al. Cardiovascular Ultrasound 2012, 10:28
http://www.cardiovascularultrasound.com/content/10/1/28RESEARCH Open AccessLeft atrial pathological degeneration assessed by
integrated backscatter transesophageal
echocardiography as a predictor of progression to
persistent atrial fibrillation: Results from a
prospective study of three-years follow-up
Tomoki Kubota, Masanori Kawasaki*, Nobuhiro Takasugi, Hajime Imai, Yoshiyuki Ishihara, Munenori Okubo,
Shigekiyo Takahashi, Hironobu Sato, Kazuhiko Nishigaki, Genzou Takemura and Shinya MinatoguchiAbstract
Background: It is recognized that one of the causes of atrial fibrillation (AF) is pathological degeneration of the left
atrium (LA). However, prospective study that elucidated the relationship between the incidence of persistent AF
and pathological degeneration has not been performed. The purpose of this study was to elucidate the usefulness
of integrated backscatter (IBS) values for the prediction of progression from paroxysmal AF (PAF) to persistent AF.
Methods: We measured IBS values of the entire LA wall at 5 mm intervals (except the posterior wall) in 27 patients
with paroxysmal AF and evaluated progression to persistent AF for three years. IBS values were acquired with
transesophageal echocardiography (TEE) using a 4–7 MHz transducer. IBS values were calculated as the average
power of the backscattered signal from regions of interest (ROI). Each IBS value was color-coded to construct three
dimensional maps.
Results: Average IBS values of total voxels in color-coded maps in the persistent AF group were significantly
greater than those in the non-persistent AF group (25.8 ± 5.0 dB vs. 17.4 ± 10.2 dB, p = 0.047), whereas there was no
significant difference in LA diameter between the persistent AF and the non-persistent AF group. There was
significant difference in persistent AF-free survival after the baseline measurements in the subjects stratified by IBS
value (<20 dB versus ≥20 dB) (univariate Cox regression analysis: hazard ratio: 8.74, p =0.046).
Conclusion: Using IBS values measured by TEE, we can identify an increase in atrial degeneration that may predict
the occurrence of persistent AF before LA dilation.
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Atrial fibrillation (AF) is the most common sustained car-
diac arrhythmia and is associated with increased mortality
and morbidity [1,2]. Left atrial (LA) structural, functional
and pathological remodeling occurs in response to condi-
tions such as tachycardia, volume and/or pressure overload,
diastolic dysfunction, ischemia and valvular disease [3]. Risk
stratification for the development of AF based on LA* Correspondence: masanori@ya2.so-net.ne.jp
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reproduction in any medium, provided the orremodeling may have a major public health impact. Para-
meters that reflect LA size such as LA dimension (LAD)
and LA volume (LAV) are markers of elevated left ventricu-
lar filling pressure and have been proposed as predictors of
AF [4-6]. However, there have been few studies that exam-
ined whether LA pathological degeneration predicts the
risk of AF, because assessment of LA function has been
limited by the lack of appropriate methods. An autopsy
study reported increased amounts of fibrosis in the atria of
patients with AF compared to those in sinus rhythm [7].
Another study reported that some of the histologicalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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crease in interstitial tissue with infiltration of fatty tissue,
interstitial fibrosis, and disruption of atrial muscle [8,9].
To predict the occurrence of AF, it is important to evalu-
ate the degeneration of LA tissue. Investigation of LA tissue
characteristics based on atrial biopsies demonstrated abnor-
mal histological features in multiple biopsy specimens in all
patients with lone AF [10]. However, atrial biopsy requires
considerable skill and often results in complications. There-
fore, there is no appropriate method to evaluate degener-
ation of the LA routinely in the clinical setting.
A promising technique to evaluate tissue characteris-
tics in vivo is integrated backscatter (IBS) ultrasound.
We have shown that IBS values of left atrium obtained
from transesophageal echocardiography (TEE) reflected
an increase in atrial degeneration that may predict the
occurrence of AF [11]. We demonstrated that the
optimal cutoffs of IBS values for the prediction of occur-
rence of AF were 20 dB [11].
The purpose of this study was to elucidate the useful-
ness of IBS values measured by TEE for the prediction
of progression from paroxysmal AF (PAF) to persistent
AF.
Methods
Subjects and study protocol
This was a prospective study that elucidated diagnostic ac-
curacies of IBS values for the prediction of the progression
from PAF to persistent AF. From January 2006 until Febru-
ary 2007, 27 patients with PAF who underwent TEE in
order to evaluate valvular disease or the presence of
thrombus in the cardiac chambers were enrolled in the
present study. Exclusion criteria include unstable angina or
myocardial infarction within the previous three months, an
ejection fraction< 30 %, chronic heart failure (≥ NYHA
III), mitral valve stenosis (mitral valve area< 2 cm2), severe
mitral regurgitation or prevalent esophageal varices. Atrial
natriuretic peptide (ANP) and brain natriuretic peptide
(BNP) were measured and conventional transthoracic echo-
cardiography (TTE) was performed at the same time as
TEE. Risk factors for coronary artery disease were evaluated
in each patient including diabetes mellitus (medication
dependent, including oral hypoglycemic drugs and insulin),
hypertension (medication-dependent only), smoking status
(current smoker or quit <6 months before the study) and
dyslipidemia (medication-dependent only). We performed
monthly electrocardiogram (ECG) examinations in all en-
rolled patients, regardless of symptoms of arrhythmia dur-
ing the follow-up period. All patients who had palpitations
and/or symptoms of arrhythmia underwent both ECG and
Holter ECG examinations to confirm progression from
PAF to persistent AF. Persistent AF was defined as AF that
was sustained >7 days or lasts <7 days but necessitates
pharmacologic or electrical cardioversion [12,13].The progression from PAF to persistent AF was con-
firmed by Holter ECG examination in all patients. We
defined the time of progression from PAF to persistent AF
as the month when the Holter ECG confirmed the progres-
sion from PAF to persistent AF. The present study was
approved by the ethics committee of our institution and
informed consent was obtained from all patients before
enrollment.
Echocardiography and IBS measurement in the clinical
study
Left ventricular end-diastolic dimension (LVEDD), left
ventricular ejection fraction (LVEF) and LAD were mea-
sured by transthoracic echocardiography (SONOS 7500,
Philips Medical Systems, Andover, MA). LA volume was
calculated using an ellipsoid model that was reported in
recommendation for chamber quantification [14]. After
those measurements, TEE was performed with a 4–
7 MHz multiplane transducer with a 7.4 mm diameter
pediatric probe to diminish patient discomfort with the
console of TTE (SONOS 7500, Philips Medical Systems,
Andover, MA). The oropharynx was anesthetized with
lidocaine before TEE. After the cardiac examination,
images of the left atrium were depicted and IBS values
of entire lateral, septal and anterior walls of the left
atrium were measured at 5 mm intervals with a small re-
gion of interest (ROI) (6 x 6 pixels, 0.3 x 0.3 mm) set at
each location as described previously (Figure 1) [11]. We
set the time gain compensation at 70 dB and the lateral
gain compensation at 70 dB at every measurement. At
this setting, the IBS value of a stainless steel needle at a
distance of 4 cm from the transducer was 63 dB. When
the frequency of the transducer was 4–7 MHz, the reso-
lution was approximately 0.2-0.4 mm assuming a sound
velocity in tissue of 1,540 m/sec. The posterior wall (an
angle span of 180 degrees between −90˚ and +90˚) was
excluded from the analysis because the wall was affected
by the diffraction and reverberation phenomena due to
the short distance from the probe and angle dependency
[15]. Therefore, IBS evaluation was performed using just
the lateral, septal and anterior walls (Figure 1). The IBS
values of the LA wall were corrected (corrected IBS:
cIBS) by subtracting the IBS values in the LA cavity near
the LA wall. We also evaluated relationship between vari-
ance of cIBS values and the progression from PAF to per-
sistent AF because it was possible that heterogeneity of the
degeneration of LA tissue affected the progression.
Construction of three-dimensional color-coded maps of
left atrium
Each IBS value was color coded to construct three-
dimensional (3D) IBS maps of the entire lateral, septal and
anterior walls of the left atrium. Three-dimensional image






Figure 1 Measurement site of left atrium. Schematic image of
the analyzed site (square). Lateral, anterior and septal walls of the
left atrium were analyzed. LA: left atrium. LV: left ventricle.
Table 1 Demographics and baseline characteristics of the
patients
progression (−) progression (+) p value
(n = 21) (n = 7)
Men, n (%) 18 (86) 6 (86) >0.99
Age, y 59 ± 14 63 ± 13 0.50
Laboratory parameters,
(mg/dl)
ANP 38 ± 42 65 ± 23 0.11
BNP 77 ± 172 139 ± 136 0.40
D-dimer 0.63 ± 0.40 1.65 ± 2.05 0.56
C-reactive protein 1.06 ± 2.07 1.98 ± 4.94 0.93
Clinical history, n (%)
Hypertension 11 (52) 4 (57) >0.99
Diabetes mellitus type 2 7 (33) 3 (43) 0.67
Current smoker 3 (14) 1 (14) >0.99
Dyslipidemia 8 (38) 1 (14) 0.37
Medication, n (%)
Statins 3 (14) 0 (0) 0.55
Antiarrhythmic medication 3 (14) 1 (14) >0.99
Calcium channel blockers 6 (29) 1 (14) 0.64
ß-blockers 6 (29) 1 (14) 0.64
ACE inhibitors or ARBs 8 (38) 3 (43) >0.99
Plus-minus values are mean ± one standard deviation. CAF: chronic atrial
fibrillation. ANP: atrial natriuretic peptide. BNP: brain natriuretic peptide. ACE:
Angiotensin converting enzyme. ARB: Angiotensin II receptor blocker.
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Virginia). We employed mean cIBS values of the entire
LA wall (except the posterior wall) to evaluate LA
degeneration.
Reproducibility and reliability of data
We previously determined inter-observer variability of
cIBS values in 30 TEE recordings that were measured by
two observers at randomly selected cross-sections. The
inter-observer variability of cIBS values was 1.1 ± 3.0 %
[16]. The inter-observer correlation coefficient was 0.98
for cIBS values. Likewise, we determined intra-observer
variability of cIBS values in 30 TEE recordings that were
measured two times by one observer at randomly
selected cross-sections. The intra-observer variability of
cIBS values was 0.5 ± 3.2 %. The intra-observer correl-
ation coefficient was 0.98 for IBS values [17]. We
determined inter-observer variability of average cIBS
values in 20 randomly selected color-coded maps that
were measured by two observers. The intra-observer
variability of the average cIBS values in color-coded
maps was 2.4 ± 2.3 %. The inter-observer agreements of
average cIBS values in color-coded maps determined by
linear regression was excellent (r =0.94, p< 0.001).
Statistical Analyses
Numerical data are expressed as the mean±one standard
deviation. The Kolmogorov-Smirnov test was used to deter-
mine if data were normally distributed. If data were not
normally distributed testing for significant differences of
each parameter was performed with a Mann–Whitney Utest between two groups. Categorical data were summar-
ized as percentages and compared using a Chi-square test.
Survival curves were plotted by the Kaplan-Meier method
and hazard ratios were calculated by univariate Cox regres-
sion analysis. A p value <0.05 was considered to be signifi-
cant. Statistical analyses were performed using Stat View
version 5.0 (SAS Institute Inc, Cray, NC, USA).Results
Patient characteristics
The patients’ clinical characteristics at baseline are listed
in Table 1. During a follow-up period of three years (me-
dian: 37 months, 25th percentile: 34 months, 75th per-
centile: 40 months), 7 of 28 (25.0 %) subjects developed
Holter electrocardiographically-confirmed persistent AF.
There were no significant differences between the two
groups in the age, history of diabetes mellitus, history of
dyslipidemia, history of hypertension, current smoking
and concomitant medication use. There were tendencies
that ANP, BNP and D-dimer in the persistent AF group
were higher than those in the non-persistent AF group.
However, there were no significant differences between
the groups.
Table 3 The diagnostic accuracies for predicting
progression from paroxysmal atrial fibrillation to
persistent atrial fibrillation
Sensitivity Specificity PPV NPV
IBS value (≥20 dB) 86 (73–99) 67 (50–84) 46 (28–64) 94 (85–100)
Data are percentages. Number in parentheses are 95 % confidence intervals.
PPV: positive predictive value. NPV: Negative predictive value.
Table 2 Ultrasound parameters of the patients
progression (−) progression (+) p value
(n = 21) (n = 7)
LAD (mm) 37.8 ± 6.3 40.2 ± 6.3 0.40
LA volume (ml) 29.1 ± 12.1 39.5 ± 29.4 0.20
LVEDD (mm) 49.6 ± 7.5 48.7 ± 5.9 0.79
LVEF (%) 64.0 ± 8.5 64.9 ± 11.9 0.84
LAA peak velocity
(cm/sec)
55.8 ± 21.3 48.1 ± 21.1 0.41
Corrected IBS
value (dB)
17.4 ± 10.2 25.8 ± 5.0 0.047
Plus-minus values are mean ± one standard deviation. CAF: chronic atrial
fibrillation. LAD: left atrial dimension. LVEDD: left ventricular end-diastolic
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Ultrasound parameters are shown in Table 2. The cIBS
values in the AF group (25.8± 5.0 mm) was significantly
greater than those in the non-AF group (17.4 ± 10.2 mm,
p =0.047). There were no significant differences of LAD,
LA volume, LVEDD, LVEF and LAA peak velocity be-
tween the two groups. Kaplan-Meier curves in Figure 2
show the difference in persistent AF-free survival after the
baseline measurements in the subjects stratified by cIBS
value (<20 dB versus ≥20 dB) (univariate Cox regression
analysis: hazard ratio: 8.74, 95 % CI: 1.04 - 73.26, p =
0.046). Diagnostic accuracies of corrected IBS value for
persistent AF were shown in Table 3. There was no rela-
tionship between the variance of cIBS values between the
progression-positive group and negative group (29.8±13.8
vs. 28.7±21.2, respectively, p =0.89).
Construction of three-dimensional color-coded maps of
left atrium
Three dimensional (3D) IBS-TEE color-coded images
were consisted of a total of 228 ± 122 pixels in each
atrium. The area with a high degree of degeneration was
indicated by red and yellow colors and no or a low de-
gree of degeneration was indicated by green and blue
colors. The 3D IB-TEE images allowed visualization of
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Figure 2 Cumulative survival free from persistent atrial fibrillation. Ka
free survival after the baseline measurements in the subjects stratified by c
≥20 dB)CI: confidence interval.LA degeneration as signified by a red color in the color-
coded maps (Figure 3). By looking at these images, we
were easily able to identify the location of areas of
degeneration in the LA wall.
Discussion
The findings in the present study demonstrated that
cIBS values in patients that developed persistent AF
were greater than those in patients that did not develop
persistent AF. However, the LAD was similar in patients
with and without persistent AF. These findings indicated
that the LA myocardium in patients with persistent AF
had already degenerated before enlargement of the left
atrium. Therefore, we may predict the patients who were
likely to progress from PAF to persistent AF by evaluat-
ing cIBS values of the left atrium. To the best of our
knowledge, this is the first prospective study to elucidate
clinically the relationship between tissue characteristics
of the left atrium and the progression to persistent AF.Degeneration of LA tissue detected by integrated
backscatter ultrasound
Ultrasound backscatter power is proportional to the dif-
ference of acoustic characteristic impedance that was
determined by the density of tissue multiplied by the
speed of sound. Because of the complex geometry of the
left atrium, the acoustic characteristic impedance is
highly variable. Based on these principles, we previously
reported that it was possible to evaluate the degener-
ation of LA tissue by applying IBS analysis to TEE [11].25 30 35 40 45
cIBS value 20dB 
cIBS value <20dB 
.74 (95% CI: 1.04 – 73.26), p=0.046
up (month)
plan-Meier curves show the difference in persistent atrial fibrillation-
IBS: corrected integrated backscatter (cIBS) value (<20 dB versus
cIBS value
0 25 50 dB







Low cIBS values High cIBS values
Figure 3 Three-dimensional integrated backscatter color-coded maps of the left atrium. The area of a high degree of degeneration (high
corrected integrated backscatter values) was indicated by red and yellow colors and no or a low degree of degeneration (low corrected









Figure 4 Receiver operating characteristic curves analysis for
predicting persistent atrial fibrillation. AUC: area under the curve.
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increased as the cIBS values of the LA wall increased
[11]. Cardiac remodeling, especially in the left atrium, is
more pronounced in patients with AF. This explanation
is supported by an autopsy study that demonstrated AF
patients had increased fibrosis in the atria compared
with patients in sinus rhythm [8]. Another study demon-
strated that some of the histological features of the left
atrium in AF patients were an increase in interstitial tis-
sue with infiltration of fatty tissue, interstitial fibrosis,
and disruption of atrial muscle [9]. The left atrium is
more susceptible to fibrosis than the ventricle, although
the precise mechanisms involved in the development of
LA fibrosis are currently unknown [18]. The left atrium
in the patients with persistent AF may be degenerated
before the enlargement of the left atrium.
Histological remodeling and functional remodeling
We previously demonstrated that there was histological
remodeling of the left atrium in PAF patients before LA
enlargement [11]. The stretched atrial tissue is asso-
ciated with an increased arrhythmogenic activity and LA
dilation, and this contributes to the perpetuation of AF
[19-21]. Our other prospective study also demonstrated
that baseline active LA emptying function (booster
pump function) assessed in sinus rhythm was reduced
regardless of LA size in patients that developed new-
onset AF, and LA functional remodeling occurred prior
to the first episode of AF [22]. Taken together, these
findings indicate that both histological and functional
LA remodeling occur prior to LA enlargement. Al-
though, the relationship between the incidence of AF
and histological remodeling has not been evaluated
prospectively, we prospectively defined the relationship
between the incidence of AF and functional remodeling.
The present study showed that cIBS values of the left
atrium could be useful to predict the patients who were
likely to progress from PAF to persistent AF. We previ-
ously compared patients with and without AF andshowed that the optimal cIBS cutoff value for the predic-
tion of AF was 20 dB [11]. In that training study, the
sensitivity and specificity for the prediction of AF were
79 % and 78 %, respectively [11]. In the present valid-
ation study, similar values of sensitivity and specificity
for the prediction of AF were obtained (86 % and 67 %,
respectively) (Figure 4).
Clinical implications
Previous studies have reported that treatment with
angiotensin converting enzyme inhibitors or angiotensin
II receptor blockers can delay the progression of PAF to
chronic AF [23-25]. The findings of the present study
suggest that it may be possible to delay the progression
of PAF to persistent AF by detecting the patients with
high degree of LA degeneration and initiating treatment
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tensin II receptor blockers.
Study limitations
There are several limitations of the present study. First,
because the number of patients in our analysis was small
and the statistical power was low, the significance of dif-
ferences in echocardiographic parameters between the
groups except for cIBS values could not be evaluated. A
large-scale prospective follow-up study will be required
in the future. Second, evaluation of echocardiographic
parameters was performed only at baseline, although
patients were followed-up for three years to determine
the incidence of persistent AF. It is possible that the pa-
tient characteristics changed during the follow-up period
of three years. Third, only patients with valvular or other
cardiac disease were enrolled. Therefore, the findings of
the present study may not be applicable to the general
population. Finally, the number of incident AF cases
may have been underestimated because some patients
with persistent AF had no symptoms and only AF epi-
sodes that were confirmed by Holter ECG were consid-
ered an endpoint.
Conclusions
Using cIBS values measured by IBS-TEE, we identified
increased degeneration in the LA wall in patients with
persistent AF, and this may be useful to predict the pro-
gression from PAF to persistent AF.
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